首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1789636

細胞和基因治療市場（按治療類型、應用、最終用戶和地區分類）

Cell and Gene Therapy Market, By Therapy Type, By Application, By End User, By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

出版日期: 2025年07月02日 | 出版商:

Coherent Market Insights | 英文 247 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

細胞和基因治療市場規模預計在 2025 年達到 377 億美元，預計到 2032 年將達到 1,255 億美元，2025 年至 2032 年的複合年成長率為 18.5%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	377億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	18.50%	2032年價值預測	1255億美元

細胞療法是透過將新細胞引入患者體內，使其生長、替換或修復受損組織來治療疾病。細胞療法可以使用多種細胞類型，包括幹細胞、淋巴細胞和樹突狀細胞。細胞療法使用來自患者自身的細胞（自體細胞）和來自捐贈者的細胞（同種異體細胞）。許多細胞療法使用經過基因重編程的成體細胞，這些細胞可以在患者體內發育成多種細胞類型。這項技術有望開發出無限數量的特定人體細胞，以滿足治療需求。

基因治療旨在修改或導入基因，以治療、預防或潛在治癒疾病。基因治療方法包括用功能正常的基因拷貝取代致病突變基因，或將新的、正確的基因拷貝導入體內。

市場動態

細胞和基因療法在現代醫療保健中發揮著重要作用，因為它提供了可用於基因調控、細胞相互作用、再生能力和重塑的概念和技術。因此，主要市場參與企業正專注於實施各種成長策略，例如產品/平台推出，預計這些策略將在預測期內推動市場成長。例如，2023 年 4 月 4 日，全球醫療保健公司 AmerisourceBergen 宣布推出其細胞和基因療法 (CGT) 整合中心。該系統可與生物製藥公司和供應商的平台整合，促進即時數據交換，並幫助協調療法開發和患者護理之間的服務。

此外，由 AmerisourceBergen 創新客戶關係管理 (CRM) 系統提供支援的跨平台 CGT 整合中心旨在透過為醫生和患者服務團隊提供整個治療方法開發和交付流程的可視性，簡化醫療流程。透過平台整合，CGT 整合中心將能夠：

加快福利調查流程，以便醫生輸入患者的登記資料後，幾乎可以立即獲得有關患者保險範圍的決定。
為醫生和護理經理提供即時治療進展和交通途徑資訊，以方便患者安排。
告知案件管理員任何狀態變化，例如推遲到達日期，以便他們可以提前與患者和看護者溝通，根據需要修改計劃的治療相關活動和停留時間。

本次調查的主要特點

本報告對全球細胞和基因治療市場進行了詳細分析，提供了預測期（2023-2030 年）的市場規模（十億美元）和年複合成長率（CAGR），以 2022 年為基準年。
它還強調了各個領域的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數概述了全球細胞和基因治療市場的主要企業。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
全球細胞和基因治療市場報告涉及該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球細胞和基因治療市場的各種策略矩陣來促進決策。

Novartis International AG
Pfizer, Inc.
Sanofi SA
Amgen, Inc.
Regeneron Pharmaceuticals, Inc.
Bluebird Bio, Inc.（Celgene Corporation）
Biogen Inc.
uniQure NV
JCR Pharmaceuticals Co. Ltd.
Gene Biotherapeutics
Kolon TissueGene, Inc.
Horama SA
MeiraGTx Limited
Gilead Sciences, Inc.
Organogenesis, Inc.
Orchard Therapeutics Plc.
Freeline Therapeutics Ltd.
Bristol-Myers Squibb Company
PTC Therapeutics, Inc.
Spark Therapeutics, Inc.
Biomarin Pharmaceutical Inc.

第9章章節

調查方法
關於出版商

簡介目錄

Product Code: CMI2475

Cell And Gene Therapy Market is estimated to be valued at USD 37.7 Bn in 2025 and is expected to reach USD 125.5 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.5% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 37.7 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	18.50%	2032 Value Projection:	USD 125.5 Bn

Cell therapy is the introduction of new cells into a patient's body to grow, replace, or repair damaged tissue in order to treat a disease. A variety of different types of cells can be used in cell therapy, including stem cells, lymphocytes, and dendritic cells. Cell therapies can use cells from the patient's own body (autologous) or from a donor (allogenic). Many cell therapies use adult cells that have been genetically reprogrammed and capable of becoming one of many types of cells inside a patient's body. This technology may enable the development of unlimited types of specific human cells needed for therapeutic purposes.

Gene therapy seeks to modify or introduce genes into a patient's body with the goal of treating, preventing, or potentially curing a disease. Examples of gene therapy approaches include replacing a mutated gene that causes disease with a functional copy or introducing a new, correct copy of a gene into the body.

Market Dynamics

Cell and gene therapy plays a major role in modern healthcare, as it provides concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling. Thus, key market players are focused on adopting various growth strategies such as product/platform launches and others, which in turn is expected to fuel the market growth over the forecast period. For instance, on April 4, 2023, AmerisourceBergen, a global healthcare company, announced the launch of its Cell and Gene Therapy (CGT) Integration Hub, a system that can be integrated with biopharma or provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the treatment development and patient journey.

Furthermore, The CGT Integration Hub, which is platform-agnostic and powered by AmerisourceBergen's innovative customer relationship management (CRM) system, aims to streamline the path-to-care process, in part, by providing physicians and patient services teams with enhanced visibility across the therapy development and delivery process. Through platform integrations, the CGT Integration Hub can

Speed up the benefits investigation process so that after physicians enter patient enrollment data, they can get a decision on the patient's coverage almost immediately.
To facilitate patient scheduling, give doctors and care managers real-time access to information on the status of the development of the therapy and transportation.
Inform case managers of any status changes, such as postponed arrival dates, so they can contact patients and caregivers in advance to amend any scheduled treatment-related activities or stays, as necessary.

Key features of the study

This report provides an in-depth analysis of the global cell and gene therapy market and provides market size (USD Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global cell and gene therapy market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., Bluebird Bio, Inc. (Celgene Corporation) , Biogen Inc., uniQure N.V., JCR Pharmaceuticals Co. Ltd., Gene Biotherapeutics, Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Organogenesis, Inc., Orchard Therapeutics Plc., Freeline Therapeutics Ltd. , Bristol-Myers Squibb Company, PTC Therapeutics, Inc., Spark Therapeutics, Inc. and Biomarin Pharmaceutical Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell and gene therapy market.

Market Segmentation

Global Cell and Gene Therapy Market, By Therapy Type
- Cell Therapy
- Stem Cells
- T Cells
- Dendritic Cells
- NK Cells
- Gene Therapy
- Germline Gene Therapy
- Somatic Gene Therapy
Global Cell and Gene Therapy Market, By Application
- Dermatology
- Musculoskeletal
- Oncology
- Immunology
- Cardiology & Neurology
- Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
Global Cell and Gene Therapy Market, By End user
- Hospitals
- Clinics
- Others (Research Institutes, Academic Institutes, etc.)
Global Cell and Gene Therapy Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players
- Novartis International AG
- Pfizer, Inc.
- Sanofi S.A.
- Amgen, Inc.
- Regeneron Pharmaceuticals, Inc.
- Bluebird Bio, Inc. (Celgene Corporation)
- Biogen Inc.
- uniQure N.V.
- JCR Pharmaceuticals Co. Ltd.
- Gene Biotherapeutics
- Kolon TissueGene, Inc.
- Horama S.A.
- MeiraGTx Limited
- Gilead Sciences, Inc.
- Organogenesis, Inc.
- Orchard Therapeutics Plc.
- Freeline Therapeutics Ltd.
- Bristol-Myers Squibb Company
- PTC Therapeutics, Inc.
- Spark Therapeutics, Inc.
- Biomarin Pharmaceutical Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Application
- Market Snapshot, By End user
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
Technological Advancements
Manufacturer Revenue
Pipeline Analysis

4. Global Cell and Gene Therapy Market, By Therapy Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020-2032
- Segment Trends
Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Segment Trends
  - Stem Cells
  - T Cells
  - Dendritic Cells
  - NK Cells
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Segment Trends
  - Germline Gene Therapy
  - Somatic Gene Therapy

5. Global Cell and Gene Therapy Market, By Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020-2032
- Segment Trends
Dermatology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Segment Trends
Musculoskeletal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Segment Trends
Immunology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Segment Trends
Cardiology & Neurology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Segment Trends
Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Segment Trends

6. Global Cell and Gene Therapy Market, By End user, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020-2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Research Institutes, Academic Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Cell and Gene Therapy Market, By Region, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End user, 2020-2032, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country , 2020-2032, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Amgen, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bluebird Bio, Inc. (Celgene Corporation)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
uniQure N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
JCR Pharmaceuticals Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gene Biotherapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Kolon TissueGene, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Horama S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
MeiraGTx Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Organogenesis, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Orchard Therapeutics Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Freeline Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
PTC Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Spark Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biomarin Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies